New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV's DPX-Survivac in Combination with Merck's Keytruda in Patients with DLBCL

Stock Information for IMV Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IMV Inc.

IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
IMV Receives NASDAQ Delisting Notice
Horizon Technology Finance Announces First Quarter 2023 Financial Results
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
IIROC Trading Halt - IMV
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
IMV Inc. Announces Changes to Its Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.